- ISIN
- US92859E1082
- CUSIP
- 92859E108
- Sector
- Healthcare
- Industry
- Medical Devices
- IPO Date
- Dec 11, 2020
Highlights
- EPS (TTM)
- -$3.18
- Total Revenue (TTM)
- $17.44M
- Gross Profit (TTM)
- $10.55M
- EBITDA (TTM)
- -$37.17M
- Year Range
- $0.40 - $7.95
- Target Price
- $2.25
- ROA (TTM)
- -84.41%
- ROE (TTM)
- 1,424.90%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
VVOS Performance Chart
Vivos Therapeutics, Inc. (VVOS) is down 80.2% since the beginning of the year. At $0 per share, VVOS is trading 94.9% below its 52-week high of $8. Investors who bought $1,000 worth of VVOS shares 5 years ago would now be looking at an investment worth $3.
Loading charts...
Returns By Period
Vivos Therapeutics, Inc. (VVOS) has returned -80.19% so far this year and -85.64% over the past 12 months.
Vivos Therapeutics, Inc.
- 1D
- -19.56%
- 1M
- -34.07%
- YTD
- -80.19%
- 6M
- -80.38%
- 1Y
- -85.64%
- 3Y*
- -67.84%
- 5Y*
- -68.14%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
VVOS Monthly Returns History
Based on dividend-adjusted daily data since Dec 11, 2020, VVOS's average daily return is +0.33%, while the average monthly return is +2.82%. At this rate, an investment would double in approximately 2.1 years.
Historically, 33% of months were positive and 67% were negative. The best month was Nov 2023 with a return of +663.2%, while the worst month was Dec 2023 at -49.2%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 10 months.
On a daily basis, VVOS closed higher 42% of trading days. The best single day was Nov 29, 2023 with a return of +833.9%, while the worst single day was Nov 30, 2023 at -40.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -20.20% | -13.58% | -15.71% | -32.19% | -12.52% | -42.54% | -80.19% | ||||||
| 2025 | -7.46% | -12.59% | -17.87% | -0.35% | -14.79% | 30.58% | 37.03% | 0.00% | -28.41% | -16.77% | -12.40% | -10.18% | -52.68% |
| 2024 | -40.76% | -21.17% | -16.87% | -47.62% | -17.39% | 6.22% | 3.61% | 17.82% | -3.69% | -3.45% | 35.32% | 25.81% | -65.51% |
| 2023 | 171.14% | -44.04% | -44.08% | 0.85% | 10.93% | 33.65% | -42.94% | -13.64% | -23.56% | -33.16% | 663.24% | -49.22% | 23.78% |
| 2022 | 9.78% | 35.22% | -19.76% | -35.45% | 17.34% | -36.45% | -10.85% | 6.96% | -47.16% | 10.79% | -30.56% | -19.60% | -82.13% |
| 2021 | 10.66% | 14.83% | -11.58% | 4.67% | -22.59% | -7.99% | -38.99% | 74.17% | -23.19% | -10.15% | -29.75% | -11.76% | -61.93% |
Benchmark Metrics
Vivos Therapeutics, Inc. has an annualized alpha of 102.80%, beta of 0.87, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since December 11, 2020.
- This stock participated in 255.75% of S&P 500 Index downside but only -47.76% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 102.80%
- Beta
- 0.87
- R²
- 0.00
- Upside Capture
- -47.76%
- Downside Capture
- 255.75%
Return for Risk
Risk / Return Rank
VVOS ranks 6 for risk / return — in the bottom 6% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Vivos Therapeutics, Inc. (VVOS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VVOS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.91 | ||
| Sortino ratioReturn per unit of downside risk | -4.92 | ||
| Omega ratioGain probability vs. loss probability | 0.76 | 1.37 | -0.60 |
| Calmar ratioReturn relative to maximum drawdown | -0.91 | 2.78 | -3.69 |
| Martin ratioReturn relative to average drawdown | -1.27 | 12.44 | -13.71 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Vivos Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Vivos Therapeutics, Inc. was 99.83%, occurring on Jun 22, 2026. The portfolio has not yet recovered.
The current Vivos Therapeutics, Inc. drawdown is 99.83%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.83%Jun 2026 | 5y 2mo | — | 5y 2moApr 2021 - now |
2020 bear market2020 | -35.13%Dec 2020 | 13d | 3mo 5d | 3mo 18dDec 2020 - Apr 2021 |
2020 bear market2020 | -24.58%Dec 2020 | 2d | 1d | 3dDec 2020 - Dec 2020 |
Drawdown Indicators
| VVOS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.83% | -56.78% | -43.05% |
Max Drawdown (1Y)Largest decline over 1 year | -94.21% | -9.10% | -85.11% |
Max Drawdown (3Y)Largest decline over 3 years | -99.02% | -18.90% | -80.12% |
Max Drawdown (5Y)Largest decline over 5 years | -99.73% | -25.43% | -74.30% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.83% | -1.80% | -98.03% |
Average DrawdownAverage peak-to-trough decline | -84.84% | -10.71% | -74.13% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 67.53% | 2.03% | +65.50% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Vivos Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Vivos Therapeutics, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for VVOS relative to other companies in the Medical Devices industry. Currently, VVOS has a P/S ratio of 0.2. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with VVOS
Add Vivos Therapeutics, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with VVOS